Cipher Pharmaceuticals (CPH) Competitors

C$17.96 -0.04 (-0.22%)

As of 05/13/2026 04:00 PM Eastern

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

Should you buy Cipher Pharmaceuticals stock or one of its competitors? MarketBeat compares Cipher Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cipher Pharmaceuticals include Cronos Group (CRON), Hydropothecary (THCX), Tilray Brands (TLRY), DRI Healthcare Trust (DHT.UN), and Knight Therapeutics (GUD). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Cipher Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Cronos Group's net margin of -1.29%. Cipher Pharmaceuticals' return on equity of 25.69% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Cronos Group currently has a consensus target price of C$4.75, indicating a potential upside of 27.01%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 5.35%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$146.59M	9.60	-C$32.78M	-C$0.02	N/A
Cipher Pharmaceuticals	C$50.94M	8.91	C$11.41M	C$1.05	17.10

4.4% of Cronos Group shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cronos Group has a beta of 1.11805, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 0.894897, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Cipher Pharmaceuticals had 2 more articles in the media than Cronos Group. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 5 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.33 beat Cipher Pharmaceuticals' score of 0.28 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cipher Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cronos Group beats Cipher Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.69% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$50.94M	8.91	C$11.41M	C$1.05	17.10

Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 5.35%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cipher Pharmaceuticals had 7 more articles in the media than Hydropothecary. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 0 mentions for Hydropothecary. Cipher Pharmaceuticals' average media sentiment score of 0.28 beat Hydropothecary's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Hydropothecary	Neutral
Cipher Pharmaceuticals	Neutral

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats Hydropothecary on 10 of the 10 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

4.1% of Tilray Brands shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Tilray Brands' net margin of -158.75%. Cipher Pharmaceuticals' return on equity of 25.69% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-158.75%	-88.06%	-1.41%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Tilray Brands currently has a consensus target price of C$13.30, indicating a potential upside of 78.28%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 5.35%. Given Tilray Brands' higher probable upside, equities analysts clearly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cipher Pharmaceuticals had 6 more articles in the media than Tilray Brands. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 1 mentions for Tilray Brands. Cipher Pharmaceuticals' average media sentiment score of 0.28 beat Tilray Brands' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cipher Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands has a beta of 3.243166, indicating that its share price is 224% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 0.894897, indicating that its share price is 11% less volatile than the broader market.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$858.28M	1.04	-C$183.24M	-C$14.63	N/A
Cipher Pharmaceuticals	C$50.94M	8.91	C$11.41M	C$1.05	17.10

Summary

Cipher Pharmaceuticals beats Tilray Brands on 10 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of DRI Healthcare Trust shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 60.82% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.69% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
DRI Healthcare Trust	5.02%	2.06%	4.22%

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential downside of 5.35%. DRI Healthcare Trust has a consensus target price of C$18.88, indicating a potential upside of 18.64%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts clearly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cipher Pharmaceuticals had 7 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 0 mentions for DRI Healthcare Trust. Cipher Pharmaceuticals' average media sentiment score of 0.28 beat DRI Healthcare Trust's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
DRI Healthcare Trust	Neutral

Cipher Pharmaceuticals has a beta of 0.894897, indicating that its share price is 11% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.347429, indicating that its share price is 65% less volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.91	C$11.41M	C$1.05	17.10
DRI Healthcare Trust	C$153.37M	5.71	C$9.73M	-C$0.91	N/A

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 12 of the 16 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Cipher Pharmaceuticals (TSE:CPH) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.91	C$11.41M	C$1.05	17.10
Knight Therapeutics	C$510.45M	1.63	-C$30.73M	C$0.06	141.50

Cipher Pharmaceuticals has a net margin of 60.82% compared to Knight Therapeutics' net margin of 1.10%. Cipher Pharmaceuticals' return on equity of 25.69% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Knight Therapeutics	1.10%	0.73%	0.51%

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Knight Therapeutics shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, suggesting a potential downside of 5.35%. Knight Therapeutics has a consensus target price of C$9.50, suggesting a potential upside of 11.90%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cipher Pharmaceuticals had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 7 mentions for Cipher Pharmaceuticals and 5 mentions for Knight Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.28 beat Knight Therapeutics' score of 0.10 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Knight Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cipher Pharmaceuticals has a beta of 0.894897, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.214451, indicating that its stock price is 121% less volatile than the broader market.

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$454.05M	C$2.09B	C$6.30B	C$11.91B
Dividend Yield	N/A	2.97%	2.79%	6.22%
P/E Ratio	17.10	5.47	21.03	36.92
Price / Sales	8.91	1,460.03	552.98	12.32
Price / Cash	3.53	10.18	42.94	82.42
Price / Book	3.42	10.95	9.82	4.65
Net Income	C$11.41M	C$20.70B	C$3.55B	C$299.62M
7 Day Performance	0.50%	0.35%	-0.53%	0.91%
1 Month Performance	-7.76%	-1.83%	1.20%	1.28%
1 Year Performance	44.03%	27.82%	41.23%	59.01%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	0.695 of 5 stars	C$17.96 -0.2%	C$17.00 -5.3%	+40.5%	C$454.05M	C$50.94M	17.10	5	News Coverage Earnings Report Analyst Forecast
CRON Cronos Group	3.0486 of 5 stars	C$3.53 -1.9%	C$4.38 +23.9%	+32.2%	C$1.33B	C$146.59M	N/A	450	News Coverage Earnings Report Analyst Forecast
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
TLRY Tilray Brands	1.3553 of 5 stars	C$7.73 -1.8%	C$13.30 +72.1%	+18.4%	C$924.54M	C$858.28M	N/A	2,650
DHT.UN DRI Healthcare Trust	N/A	C$16.05 -0.7%	C$18.88 +17.6%	+27.9%	C$883.02M	C$153.37M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

How does Cipher Pharmaceuticals compare to Cronos Group?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

How does Cipher Pharmaceuticals compare to Cronos Group?

Is CRON or CPH more profitable?

Do analysts prefer CRON or CPH?

Which has stronger valuation and earnings, CRON or CPH?

Do insiders & institutionals believe in CRON or CPH?

Which has more risk and volatility, CRON or CPH?

Does the media refer more to CRON or CPH?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Is THCX or CPH more profitable?

Which has higher valuation & earnings, THCX or CPH?

Do analysts prefer THCX or CPH?

Does the media favor THCX or CPH?

Do institutionals & insiders believe in THCX or CPH?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Do institutionals & insiders believe in TLRY or CPH?

Is TLRY or CPH more profitable?

Do analysts prefer TLRY or CPH?

Does the media prefer TLRY or CPH?

Which has more volatility & risk, TLRY or CPH?

Which has higher valuation & earnings, TLRY or CPH?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Do insiders and institutionals have more ownership in CPH or DHT.UN?

Is CPH or DHT.UN more profitable?

Do analysts recommend CPH or DHT.UN?

Does the media favor CPH or DHT.UN?

Which has more volatility & risk, CPH or DHT.UN?

Which has better earnings and valuation, CPH or DHT.UN?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Which has preferable valuation & earnings, CPH or GUD?

Is CPH or GUD more profitable?

Do institutionals and insiders hold more shares of CPH or GUD?

Do analysts recommend CPH or GUD?

Does the media favor CPH or GUD?

Which has more volatility and risk, CPH or GUD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools